A Study of JZP150 in Adults With Posttraumatic Stress Disorder

Study Status: Completed

JZP150 is an oral, highly selective inhibitor of fatty acid amide hydrolase (FAAH). In this phase 2 study, participants with PTSD will receive either placebo or 1 of 2 doses of JZP150. The primary objective of the study will assess the change in PTSD symptoms from baseline to Week 12 using the Clinician Administered PTSD Scale (CAPS-5).

  • Sex: ALL
  • Minimum Age: 18 Years
  • Maximum Age: 70 Years

Researchers look for people who fit a certain description, called eligibility criteria. Below are the inclusion and exclusion criteria for study participants:

Inclusion Criteria

  • Participants aged 18 to 70 years
  • Participants must be outpatients with a primary diagnosis of Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) defined PTSD confirmed by the clinical interview
  • PTSD is primary diagnosis

Exlusion Criteria

  • Acute or unstable medical condition, behavioral or psychiatric disorder (other than PTSD)
  • Suicidal behavior in the past 2 years or active suicidal ideation in the past 6 months
  • Ongoing traumatic event or exposure to a traumatic event <3 months prior to Screening
  • Index event > 12 years
  • Index event is combat trauma

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Post Traumatic Stress Disorder

Intervention/Treatment

Intervention/Treatment

  • DRUG : JZP150
  • DRUG : Placebo

Sponsor

Jazz Pharmaceuticals

Phase

  • PHASE2